As demand for medical supplies soars worldwide in the fight against Covid-19, there is a parallel risk of substandard and counterfeit medicines in the global market. With India being one of the world's largest producers of medical supplies, there is an urgent need to bring in strong anti-counterfeiting measures which will be addressed at Messe Frankfurt’s upcoming conference - Pharmasafe India 2020.
Together with healthcare workers on the frontline, the pharmaceutical industry has been actively playing a crucial role and strengthening efforts to ensure best medical services in the battle against Covid-19. However, the trade of counterfeit medicines, which can pose a direct threat to public health and life, has found resurgence in the wake of on-going pandemic. The recent warnings issued by the World Health Organisation indicate that a growing number of fake medicines linked to coronavirus are on sale in developing countries. There have already been multiple incidents reported on the sale of counterfeit facemasks, substandard hand sanitisers, substandard PPE's as well as counterfeit anti-viral drugs to unsuspecting consumers.
With an aim to draw attention to the latest developments in the field of anti-counterfeiting technologies for the pharma industry, Messe Frankfurt India will bring key anti-counterfeit solution providers for dialog with the pharma sector at its highly influential Pharmasafe India 2020 conference. The 4th edition of the conference, which was earlier scheduled in April, has now been pushed ahead due to the nationwide lockdown and the new dates will be announced in the coming weeks, when the industry can safely and surely come together to address and reinforce measures for this global issue.
Ahead of the conference scheduled this year, Messe Frankfurt is also organising a series of Webinars during the lockdown period to serve the industry with valuable insights from an international panel of experts and thereby helping the industry in charting anti-counterfeiting strategies in the current situation. While the webinars will bring attention to immediate topics of relooking at patient safety by eliminating substandard products in the wake of global outbreak, the organiser is working towards addressing burning topics around Covid-19 at the Pharmasafe India conference taking place later this year, surrounding the counterfeit market such as the race for coronavirus vaccine and government initiatives to prevent vaccine counterfeit, Operation Pangea 13: key findings and importance of consolidated global efforts in identifying counterfeit networks, strengthening supply chain and traceability technology to curb counterfeit amid pandemic, mishandling of medicines and addressing the issue of improper vaccine storage and how the pandemic is reshaping brand protection.
The conference has drawn strong support from leading associations in the pharmaceutical industry including Authentication Solution Providers' Association (ASPA), Indian Drug Manufacturers' Association (IDMA), Cell for IPR Promotion and Management (CIPAM) and Chamber of Business Leaders.
According to a study conducted by the OECD and the European Union Intellectual Property Office, trade in counterfeit pharmaceutical products worldwide is worth just over €4bn. The longer the pandemic lasts, the more strain supply chains and distribution channels will undergo, making it easy for counterfeits or sub-standard medical products to enter the market. It is crucial to simultaneously focus on anti-counterfeiting and brand protection strategies which Pharmasafe India 2020 together with its webinar series aim to achieve through the combined efforts of technology experts, decision-makers and the Indian pharma industry.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has granted marketing authorisation for DARZALEX®? (daratumumab) subcutaneous (SC) formulation for the treatment of adult patients with multiple myeloma (MM). Daratumumab SC is administered as a fixed dose, which significantly reduces treatment time, from hours to approximately three to five minutes, when compared to daratumumab intravenous (IV) formulation. In addition, only the first dose of daratumumab SC needs to be administered in an environment where resuscitation facilities are available. The approval applies to all current daratumumab indications in frontline and relapsed/refractory settings, and patients currently on daratumumab IV can switch to the SC formulation should they choose to.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
